Cover Image
市場調查報告書

急性肺傷害:開發中產品分析

Acute Lung Injury - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 229781
出版日期 內容資訊 英文 114 Pages
訂單完成後即時交付
價格
Back to Top
急性肺傷害:開發中產品分析 Acute Lung Injury - Pipeline Review, H1 2016
出版日期: 2016年06月22日 內容資訊: 英文 114 Pages
簡介

所謂急性肺損傷(ALI)是沒有左心房高血壓所引起的急性、重度缺氧症狀這個特徵的一般疾病。ALI是全身性發炎過程,全身性敗血症是最頻繁常見的症狀,在肺或其他組織也都會出現同樣的症狀。ALI的主要病因有敗血症及燒燙傷、放射線、吸入有害瓦斯、脂肪栓塞症等。主要症狀有極度呼吸窘迫、低血壓、意識低迷、極度的倦怠感等。

本報告提供全球各國治療急性肺傷害(急性肺損傷·障礙)所用的開發中產品開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

急性肺傷害概要

治療藥的開發

  • 急性肺傷害開發中產品:概要
  • 急性肺傷害開發中產品:比較分析

各企業開發中的急性肺傷害治療藥

大學/研究機關研究中的急性肺傷害治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

急性肺傷害治療藥:開發中的產品一覽(各企業)

急性肺傷害治療藥:研究中的產品一覽(大學/研究機關別)

急性肺傷害開發治療藥的企業

  • Altor BioScience Corporation
  • Apeptico Forschung und Entwicklung GmbH
  • Commence Bio, Inc.
  • CompleGen, Inc.
  • FirstString Research, Inc.
  • GlaxoSmithKline Plc
  • Histocell S.L.
  • Navigen Pharmaceuticals, Inc.
  • Noxxon Pharma AG
  • Quark Pharmaceuticals, Inc.
  • S-Evans Biosciences, Inc.
  • Silence Therapeutics Plc
  • Stemedica Cell Technologies, Inc.
  • Windtree Therapeutics, Inc.

急性肺傷害:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

急性肺傷害治療藥:暫停的計劃

急性肺傷害治療藥:開發中止的產品

急性肺傷害相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8169IDB

Summary

Global Markets Direct's, 'Acute Lung Injury - Pipeline Review, H1 2016', provides an overview of the Acute Lung Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Lung Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Lung Injury and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Lung Injury
  • The report reviews pipeline therapeutics for Acute Lung Injury by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acute Lung Injury therapeutics and enlists all their major and minor projects
  • The report assesses Acute Lung Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acute Lung Injury

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acute Lung Injury
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acute Lung Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Acute Lung Injury Overview
  • Therapeutics Development
    • Pipeline Products for Acute Lung Injury - Overview
    • Pipeline Products for Acute Lung Injury - Comparative Analysis
  • Acute Lung Injury - Therapeutics under Development by Companies
  • Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes
  • Acute Lung Injury - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Acute Lung Injury - Products under Development by Companies
  • Acute Lung Injury - Products under Investigation by Universities/Institutes
  • Acute Lung Injury - Companies Involved in Therapeutics Development
    • Altor BioScience Corporation
    • Apeptico Forschung und Entwicklung GmbH
    • Commence Bio, Inc.
    • CompleGen, Inc.
    • FirstString Research, Inc.
    • GlaxoSmithKline Plc
    • Histocell S.L.
    • Navigen Pharmaceuticals, Inc.
    • Noxxon Pharma AG
    • Quark Pharmaceuticals, Inc.
    • S-Evans Biosciences, Inc.
    • Silence Therapeutics Plc
    • Stemedica Cell Technologies, Inc.
    • Windtree Therapeutics, Inc.
  • Acute Lung Injury - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALT-836 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Atu-111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BC-1215 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-10901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CGX-1037 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMB-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FAB-117-HC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2586881 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2862277 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-Citrulline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LTI-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lucinactant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MG-53 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAV-2729 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXD-19 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P- BEFizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Activate PAI-1 for Acute Lung Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QPLI-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-10001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-911 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-1229 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solnatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Acute Lung Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Acute Lung Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure and Neurodegenerative Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Respiratory Distress Syndrome and Acute Lung Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TXA-302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Acute Lung Injury - Dormant Projects
  • Acute Lung Injury - Discontinued Products
  • Acute Lung Injury - Product Development Milestones
    • Featured News & Press Releases
      • Jul 30, 2015: Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury
      • Aug 05, 2014: Silence Therapeutics Announces Publication of pre-clinical study data on use of Atu111 RNAi in sepsis
      • Oct 08, 2013: Discovery Labs Announces Notice of Allowance for a U.S. Patent Supporting the AEROSURF Development Program
      • Sep 27, 2012: Discovery Labs Initiates Research Projects With Research Institutions And US Government Agencies To Assess KL(4) Surfactant Utility In Acute Lung Injury
      • Sep 10, 2012: Silence Therapeutics' Proof of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics
      • Dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase IIa Study In Acute Lung Injury Patients
      • May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI
      • Apr 20, 2011: Discovery Labs's KL4 Surfactant Aerosolization Program Data To Be Presented At Pediatric Academic Societies Annual Meeting
      • Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acute Lung Injury, H1 2016
  • Number of Products under Development for Acute Lung Injury - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Acute Lung Injury - Pipeline by Altor BioScience Corporation, H1 2016
  • Acute Lung Injury - Pipeline by Apeptico Forschung und Entwicklung GmbH, H1 2016
  • Acute Lung Injury - Pipeline by Commence Bio, Inc., H1 2016
  • Acute Lung Injury - Pipeline by CompleGen, Inc., H1 2016
  • Acute Lung Injury - Pipeline by FirstString Research, Inc., H1 2016
  • Acute Lung Injury - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Acute Lung Injury - Pipeline by Histocell S.L., H1 2016
  • Acute Lung Injury - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016
  • Acute Lung Injury - Pipeline by Noxxon Pharma AG, H1 2016
  • Acute Lung Injury - Pipeline by Quark Pharmaceuticals, Inc., H1 2016
  • Acute Lung Injury - Pipeline by S-Evans Biosciences, Inc., H1 2016
  • Acute Lung Injury - Pipeline by Silence Therapeutics Plc, H1 2016
  • Acute Lung Injury - Pipeline by Stemedica Cell Technologies, Inc., H1 2016
  • Acute Lung Injury - Pipeline by Windtree Therapeutics, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Acute Lung Injury - Dormant Projects, H1 2016
  • Acute Lung Injury - Dormant Projects (Contd..1), H1 2016
  • Acute Lung Injury - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Acute Lung Injury, H1 2016
  • Number of Products under Development for Acute Lung Injury - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top